Figure 7. Liver ILC1-derived IFN-γ is sufficient to ameliorate CCl₄-induced acute liver injury.

(A) Experimental design of ILC1 transfer into Rag2^−/−Il2rg^−/− mice. (B) Phenotypical characterization of donor-derived ILC1 in the liver of recipient Rag2^−/−Il2rg^−/− mice that had been transferred with purified donor ILC1 together with or without IL-15 (n = 2–4). (C) The number of donor-derived ILC1 in the liver of recipient Rag2^−/−Il2rg^−/− mice that had been transferred with purified donor ILC1 together with or without IL-15. Data were pooled from 4 experiments (n = 4). (D) Expression of CD25 on donor-derived ILC1 in the liver of Rag2^−/−Il2rg^−/− mice (that had been transferred with purified donor ILC1 together with IL-15) before (naïve) and 18 h after CCl₄ injection on day 7 post-transfer (n = 2–3). (E) MFI of CD25 on donor-derived ILC1 in the liver of Rag2^−/−Il2rg^−/− mice (that had been transferred with purified donor ILC1 together with IL-15) before and 18 h after CCl₄ injection on day 7 post-transfer. Data were pooled from 2 experiments (n = 4). (F) Expression of CD69 on donor-derived ILC1, CD25⁻ ILC1, and CD25⁺ ILC1 in the liver of Rag2^−/−Il2rg^−/− mice (that had been transferred with purified donor ILC1 together with IL-15) before and 18 h after CCl₄ injection on day 7 post-transfer (n = 2–3). (G) MFI of CD69 on donor-derived CD25⁻ ILC1 and CD25⁺ ILC1 in the liver of Rag2^−/−Il2rg^−/− mice (that had been transferred with purified donor ILC1 together with IL-15) before and 18 h after CCl₄ injection on day 7 post-transfer. Data were pooled from 2 experiments (n = 4). (H) Kinetics of IFN-γ⁺ cells in donor-derived CD25⁻ ILC1 and CD25⁺ ILC1 in the liver of Rag2^−/−Il2rg^−/− mice (that had been transferred with purified donor ILC1 together with IL-15) after CCl₄ injection. Data were pooled from 4 experiments (n = 5–15). *p<0.005 vs. CD25⁻ ILC1. (I) The percentages of IFN-γ⁺ cells in donor-derived ILC1, CD25⁻ ILC1, and CD25⁺ ILC1 in the liver of Rag2^−/−Il2rg^−/− mice (that had been transferred with purified donor ILC1 together with IL-15) before and 15 h after CCl₄ injection (n = 4–6). (J) The percentages of IFN-γ⁺ cells in donor-derived CD25⁻ ILC1 and CD25⁺ ILC1 in the liver of Rag2^−/−Il2rg^−/− mice (that had been transferred with purified donor ILC1 together with IL-15) before and 15 h after CCl₄ injection (n = 4–6). (K) Plasma concentrations of ALT in Rag2^−/−Il2rg^−/− mice (that had been transferred or not with purified donor ILC1 together with IL-15) before and 18 h after CCl₄ injection on day 7 post-transfer, which were also injected with a depletion anti-CD25 mAb (left), a neutralizing anti-IFN-γ mAb (right), or isotype Ig 6 h before and 6 h after CCl₄ injection. Data were pooled from 2 (left) (n = 4–5) and 3 (right) (n = 6–7) experiments. Data are representative of 4 (B) and 3 (D, F, I, and J) independent experiments. *p<0.05, **p<0.01, ***p<0.005. Error bars show s.d. See also Figure S7.